Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Presumptive Versus Definitive Drug Testing: What Are We Missing

PAINWeek Conference 2021

September 7-11, 2021, Las Vegas, NV

Presumptive versus definitive drug testing: What are we missing

Authors: Jeffrey Gudin, Jack Kain, Les Edinboro, Lee Hilborne

Specialties: Prescription Drug Monitoring, Toxicology, Pain Management

Download key summary

Related content

Audio Podcast
Presumptive vs Definitive Drug Testing: What You Need to Know
Audio Podcast
Windows of Detection
Publication
Implementation of the first comprehensive state oral fluid drug testing program for roadside screening and laboratory testing in DUID cases - a five-year review
Conference Presentation
“How Am I Suppose to Analyze That?!” A Master Class in Sample Preparation and Matrix Understanding: Oral Fluid Discussion
Conference Presentation
Prevalence of Novel Psychoactive Substances in Routine Prescription Drug Monitoring Clinical Urine Specimens
Test FAQ
Novel Psychoactive Substances (NPS) Panel
Test FAQ
Drug Toxicology Monitoring Oral Fluid Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.